Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancerKatrin J. Frank, Sara Mainardi, Antonio Mulero‐Sánchez et al.|Cell Reports Medicine|2022Cited by 39
Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma MultiformeFiliz Senbabaoglu, Tugba Bagcı-Önder, Ahmet Cingöz et al.|Cancer Biology & Therapy|2016Cited by 35
Combined SHP2 and ERK inhibition for the treatment of KRAS-driven Pancreatic Ductal AdenocarcinomaKatrin J. Ciecielski, Sara Mainardi, Yuhui Fan et al.|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 2
Abstract B73: Screen among 1200 FDA-approved drug library reveals mitoxantrone as a TRAIL-sensitizing agent for glioblastoma multiformeFiliz Senbabaoglu, Tugba Bagcı-Önder, Ahmet Cingöz et al.|Molecular Cancer Therapeutics|2015Cited by 0
Mitoxantrone as a TRAIL-sensitizing agent for glioblastoma multiformeFiliz Senbabaoglu, Tugba Bagcı-Önder, Ahmet Cingöz et al.|European Journal of Cancer|2016Cited by 0